Christian Schwarzer Velazquez @Khrix69: "💊🚨 $HIMS A BROKEN THESIS!..."

Spain

💊🚨 $HIMS (Hims & Hers Health Inc) A BROKEN THESIS! Everything it could have been… Everything a company should NOT do. 💔💀 My portfolio is made up of parameters, values, and a management team that executes these fundamentals. In other words, most of the companies I hold go through a series of filters which, once passed, lead me to consider adding them to the portfolio if expectations and price are optimal. One of these parameters — and probably one of the most important — which speaks to the company’s culture and the quality of its decisions, is sacrificing the short term for the long term. That is, consciously sacrificing the next few quarters, margins, and generating an optically lower profit than you could achieve, in order to increase the company’s terminal value, consolidate a competitive advantage over many years, and, with a high ROIC, allow these investments to compound over time. A good example of a company that does this exceptionally well is $AMZN (Amazon.com Inc) In the latest earnings call, Andy Jassy made it very clear: they are going to invest heavily in data centers and AI. The market expected $145B and they will end up investing $200B, and they told you directly that they expect this investment to be fruitful in the long term thanks to their high return on invested capital. This is why the stock fell sharply last week, and these, from my point of view, are the best opportunities in the market, where you are almost guaranteed to make money in the long term. A company that suffers in the short term because it chooses to, not because it is actually struggling. On the other hand, we have $HIMS a company I previously held and which was my top position for several months. I discovered it very early, with my first purchase around $12. I significantly increased my position at $16, and when it corrected sharply again, I bought in April 2025 at $26. After being up nearly 300%, the stock fell sharply when it broke its partnership with $NVO (Novo-Nordisk A/S SPONS ADR) just a few weeks after announcing that alliance. I didn’t like that at all. I saw a potential risk to the thesis that changed my perspective, and I sold around $45. The stock later went back up to $60, but I remained very skeptical. Today it is trading below $20, as it is expected to continue falling sharply on Monday following the news that the FDA is going to investigate $HIMS for improper practices that could put patients at risk and patent infringement. $HIMS is much more than GLP-1. It is a company with multiple verticals, and my thesis was that they would continue expanding them, gradually diversifying and becoming a more holistic and integrated company. Instead, what Dudum is doing with the company is the exact opposite. $HIMS has started playing with fire, taking on the pharmaceutical giant $NVO, which is larger, has more resources, and holds the FDA patents for GLP-1. They attempted to commercialize a drug without certainty that it is 100% safe for the patient, purely to boost short-term profits in upcoming quarters and to position themselves as the “champion” of Big Pharma. While I have always been clear that $HIMS aims to democratize access to medications to make them more affordable for patients, as well as provide the relevant treatments $HIMS is no more than another pharmaceutical company generating profits at the expense of patients, giving them a patch without addressing the root cause. They are no different from other pharmaceutical companies and benefit from a sick population. Simply, thanks to their asset-light business model, which allows them to cut costs along the value chain, they can offer these treatments more cheaply. But they are still part of Big Pharma. They are not “saviors”; this is pure marketing. Regarding the dilemma: $NVO oral semaglutide has a patented formulation called “SNAC”, which is a compound that allows the body to properly process the pill so that the drug becomes bioavailable. Without $NVO patented technology, the drug’s bioavailability could be zero and could even cause side effects if absorption is irregular. I continue in Comments --->> $HIMS $SPX500 $NSDQ100 $AMZN $NVO

5 Mentioned

HIMS

Hims & Hers Health Inc

AMZN

Amazon.com Inc

NVO

Novo-Nordisk A/S SPONS ADR

SPX500

NSDQ100

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies